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Abstract
Plasmodium vivax Duffy binding protein region II (DBPII) is an important vaccine candidate for antibody-mediated immunity
against vivax malaria. A significant challenge for vaccine development of DBPII is its highly polymorphic nature that alters
sensitivity to neutralizing antibody responses. Here, we aim to characterize naturally-acquired neutralizing antibodies
against DBPII in individual Thai residents to give insight into P. vivax vaccine development in Thailand. Anti-DBPII IgG
significantly increased in acute vivax infections compared to uninfected residents and naive controls. Antibody titers and
functional anti-DBPII inhibition varied widely and there was no association between titer and inhibition activity. Most high
titer plasmas had only a moderate to no functional inhibitory effect on DBP binding to erythrocytes, indicating the
protective immunity against DBPII binding is strain specific. Only 5 of 54 samples were highly inhibitory against DBP
erythrocyte-binding function. Previously identified target epitopes of inhibitory anti-DBPPII IgG (H1, H2 and H3) were
localized to the dimer interface that forms the DARC binding pocket. Amino acid polymorphisms (monomorphic or
dimorphic) in H1 and H3 protective epitopes change sensitivity of immune inhibition by alteration of neutralizing antibody
recognition. The present study indicates Thai variant H1.T1 (R308S), H3.T1 (D384G) and H3.T3 (K386N) are the most
important variants for a DBPII candidate vaccine needed to protect P. vivax in Thai residents.
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Introduction
Plasmodium vivax is a cause of morbidity and mortality in
Thailand and other countries in South East Asia and worldwide
about three billion people live at risk of infection by P. vivax [1,2].
Current public health surveys indicates vivax malaria prevalence
has been on the rise in Thailand and P. vivax now accounts for
more than 50% of all malaria cases since 2000 [3,4]. Approxi-
mately 50% of the cases are in the migrant population. Vivax
malaria is widespread and still an important problem in Thai-
Cambodia border and Southern parts of Thailand in the Malayan
peninsula. It is important to note that a significant portion of
malaria cases in Thailand occur among temporary migrant
workers from bordering countries [5], which presents a major
challenge to prevention and control of malaria in the resident
population.
Plasmodium blood stages are responsible for clinical manifestation
during infection. In P. vivax the blood stage preferentially invades
reticulocytes expressing the Duffy Antigen Receptor for Chemo-
kines (DARC) [6]. Parasite ligands, Reticulocyte binding proteins
(RBPs) and Duffy binding protein (DBP), respectively, mediate
these critical invasion preferences for P. vivax [7,8,9]. Initial
interactions are believed to be mediated by RBPs, which are a
complex heterogeneous multi-gene family whose cognate receptors
are undetermined [9,10]. DBP is the product of a single copy gene
and is a member of the Duffy binding-like erythrocyte binding
protein family (DBL-EBP) family, which are expressed in the
micronemes and on the surface of P. vivax merozoites, and is
associated with the decisive junction formation step during the
invasion process [8]. It is this critical interaction of DBP with its
cognate receptor DARC that makes DBP an important anti-vivax
vaccine candidate.
The erythrocyte binding motif of DBP is in a 330-amino-acid
cysteine rich domain, referred to as DBP region II (DBPII) or the
DBL domain, and is the minimal domain responsible for binding
to DARC on Duffy-positive human erythrocytes [10,11]. DBPII is
an important vaccine candidate since anti-DBPII antibody inhibits
in vitro binding to DARC, reduces merozoite invasion of human
erythrocyte and can confer protection against blood stage infection
[12,13,14,15]. However, the analysis dbpII alleles in field parasites
showed that DBPII is hypervariable compared to other DBP
regions. The polymorphisms occur frequently at certain residues in
a pattern consistent with selection pressure on DBP, suggesting
that allelic variation functions as a mechanism for immune evasion
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vaccine efficacy [16,17,18]. Understanding protective immunity
against DBPII haplotypes common in vivax endemic area is
necessary for finding strategy for vaccine design.
In Thailand, a previous study found a high rate of nonsynon-
ymous polymorphism of dbpII alleles among 30 Thai isolates. The
highest frequency of polymorphism was found in residues D384G,
R390H,L424I,W437R andI503K[19].The phylogeneticanalysis
of dbpII Thai P. vivax isolates demonstrated that most Thai isolates
shared distinct alleles with P. vivax isolates from different geograph-
ical areas with some allele groups so far unique to Thailand [19].
Since DBPII polymorphisms among Thai isolates are extensive and
some are unique, understanding naturally protective antibody
against DBPII needs to be defined. In this study, we evaluated
immune antibody activity directed against the most common Thai
DBPII epitopes for their functional inhibition of DBPII.
Results
Naturally acquired responses to total (PvSE) and DBPII
To assess the immunological responses during P. vivax infection,
the reactivity of naturally acquired antibodies were tested against
crude schizont antigen (PvSE) and the vaccine candidate DBPII.
The anti-PvSE responses were very low in acutely infected P. vivax
patients (average OD=0.3860.13), which had average antibody
levels not significantly different from uninfected residents in the
villages of the malaria endemic areas in Thailand (average
OD=0.4460.25) and naı ¨ve controls (average
OD=0.3860.14)(Fig. 1A). In contrast the antibody titer specific
to anti-DBPII responses in individual patient’s plasma samples
were significantly elevated during P. vivax infections (average
OD=0.8160.50) when compared with that of uninfected
residents (average OD= 0.4360.18) and naı ¨ve controls (average
OD=0.1760.11)(Fig. 1B). In spite of this increased reactivity
evident during vivax malaria infections, anti-DBPII responses of
the Thai patients did not reveal any association between the
parasitemia levels and the ages of patients (data not shown). The
wide range of antibody responses to the recombinant DBPII
antigen suggested a potential protective role of higher titer anti-
DBP antibodies during P. vivax infection.
The relationship between anti-DBPII response and the
inhibitory function in Thai plasmas
To further examine potential correlations with anti-DBP
functional inhibition, anti-DBPII titers in individual patients were
classified into 3 responder groups, high (HR), low (LR) and non-
responders (NR). There were 15 samples in H group (OD value
2.24 to 1.08), 20 samples in L group (OD value 1.08 to 0.51) and
19 samples in N group (OD value less than 0.51), (Table 1).
Inhibitory activity of Thai residents of P. vivax-endemic areas were
evaluated to determine if their anti-DBPII levels correlated with
functional inhibition of DBPII binding to human erythrocytes,
(Table 1). The functional inhibitory efficiency of these samples to
inhibit DBPII binding was determined using the in vitro COS7
erythrocyte binding assay and a wide range of DBPII inhibition
was observed among Thai residents. Relatively few samples were
completely inhibitory with only 3 samples of the HR group and 2
samples of the LR group at or near 100% inhibition (54 samples,
Table 1). Most of the high anti-DBP titer samples had moderate to
no anti-DBP inhibition. Importantly, anti-DBPII functional
efficacy in Thai vivax patients did not correlate with anti-DBP
titer (Spearman’s coefficient: 0.042; P=0.764)(Fig. 2).
Anti-Thai DBPII epitopes inhibition of erythrocyte
binding
To elucidate potential differences in DBPII epitope specificity
and the preferred epitope targets for a protective vaccine
candidate in the Thai population, we affinity-purified antibodies
on peptides from defined neutralizing epitopes in DBPII. For this
analysis we pooled samples identified as highly inhibitory, which
were 3 high responder and 2 low responder samples. The anti-H1,
H2, and H3 antibodies were tested for inhibitory activity against
DBPII-Sal I binding to Duffy positive erythrocytes. The anti-H1,
H2, and H3 affinity-purified antibodies showed significantly
(P,0.05) stronger inhibition compared to purified antibodies
specific to NI peptides (Fig. 3A). Inhibitory activity increased with
the amount of neutralizing antibodies at 1, 2, 4 and 8 mg/mL. At
8 mg/mL of anti-H1, –H2 and –H3 had the highest inhibition, 95,
88 and 86%, respectively. Comparison of functional inhibition of
total purified IgG from pooled inhibitory samples showed a more
significant inhibition than total IgG of non-inhibitory samples
(P,0.001, data not shown). Purified anti-H1, H2 and H3 rabbit
sera also had an inhibitory effect against DBPII-Sal I binding but
less than in the naturally-acquired inhibitory antibodies of Thai
vivax patients (data not shown). Functional inhibitory activity of
antibodies affinity purified to Thai DBPII epitopes (H1.T1,
H3.T1, H3.T2, H3.T3 and M3.T1) was assessed by purification
from pooled inhibitory plasma and tested using the COS7 assay.
At 8 mg/mL of purified antibody had inhibitory function in range
of 96–73%. Anti-H3.T2 had the strongest inhibition (96%)
whereas anti-H1.T1 had the lowest inhibition (73%) against
DBPII-Sal I binding to erythrocytes compare to purified antibody
specific to other Thai DBPII epitopes (Fig. 3B).
To further assess impact of Thai DBPII polymorphisms to alter
the specificity of an acquired antibody responses, we compared
blocking function against Sal 1 DBPII of antibody affinity-purified
on DBPII peptide of reference Sal I stain (H group) with Thai
strain epitopes (Figs 3C, 3D). At 2 mg/mL, anti-H1.T1:
FHSDITFRKLYLKRKL (49% inhibition) significantly decreased
sensitivity of immune inhibition activity compare to anti-H1 Sal 1:
FHRDITFRKLYLKRKL (76% inhibition, P,0.001)(Fig. 3C).
Similarly, anti-H3.T1: GENAQQEEKQWWNESK (66% inhibi-
tion) had a inhibitory activity lower than anti-H3 Sal 1:
DEKAQQRRKQWWNESK (76% inhibition) (Fig. 3D). The
Figure 1. The antibody levels specific to P. vivax antigen.
Graphical display of antibody levels anti-P. vivax shizont protein extract
(A) and anti-DBPII (B) in Thai patients (PV), uninfected residents (UR) and
naı ¨ve controls (NC). Dots represent the mean optical density value in
triplicate wells for each sample. Bars represent mean value. Asterisk
indicate statistic significant at P,0.05 with non-parametric two
independent tests.
doi:10.1371/journal.pone.0035769.g001
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(R308S, D384G and K386N) of Thai DBPII epitopes alter
immune inhibition of DBP binding.
Discussion
Antibody responses have an important role in protection against
blood-stage Plasmodium infections. However, the complex blood
stage cycle and the variation of target antigens hinder the
effectiveness of humoral and cellular immune responses in defense
against the parasite [20,21,22]. Naturally acquired anti-DBP
antibody has the potential to block or inhibit parasite invasion
[13,15] and there is expected to be a boosting effect due to
repeated exposure through recurrent infection [23]. Plasmodium
vivax invasion requires the specific binding between P. vivax ligand,
DBP and DARC receptor, making DBP a high priority anti-vivax
vaccine candidate for malaria control. The characterization of
naturally acquired anti-DBPII response is strain specific. The
polymorphic nature of DBPII with each DBPII haplotype alters
antibody recognition, and has an important role to evade host
immune responses. The challenge of a DBPII vaccine is to
overcome DBPII variation by understanding the nature of strain-
specific anti-DBPII protective immunity. An effective DBPII
vaccine will need to induce effective functional inhibition against
all potential DBPII variants that circulate in malaria endemic
areas. Here, we seek to identify variants that might influence
efficacy of a DBPII vaccine in Thailand where there is low malaria
transmission occurs with multiple-clone P. vivax infection. We first
investigated the naturally acquired anti-DBPII response in
individual Thai vivax patients and define the potential DBPII
epitopes that could be protective vaccine candidate in Thailand.
Our study confirms the efficiency of naturally acquired anti-
DBPII in protection against P. vivax infection previously demon-
strated in Brazil and Papua New Guinea (PNG) vivax-endemic
areas [12]. Anti-DBPII responses in acute Thai vivax patients were
significantly higher than uninfected residents and their antibodies
inhibited DBPII binding to Duffy positive erythrocytes. The result
suggests the efficiency of naturally anti-DBPII in protection against
P. vivax can have an active role in controlling P. vivax infections.
The goal of DBPII-based vaccine development will be to elicit an
antibody response against conserved epitopes that inhibits the
adhesion of the DBPII ligand to its cognate erythrocyte receptor to
block merozoite invasion of reticulocytes.
In the present study, we showed that the natural exposure to P.
vivax in area of low unstable transmission of Thailand induced
anti-DBP antibody that strongly inhibited DBPII binding. The
inhibition activity of anti-DBPII in individual Thai residents did
not show positive correlation with anti-DBPII responses and
showed the wide range in inhibition activity. Two samples in low
responder had a high inhibition and most high responders poorly
inhibited DBPII binding. This is consistent with the study in PNG
[14] and Brazil areas [12] in which anti-DBPII activity varied
among vivax residents and also in another vaccine candidate,
EBA-175, a wide range of functional antibody among lifelong
resident of malaria holoendemic area in western Kenya [24]. To
understand the variability of anti-DBPII inhibition, one possible
explanation is the DBPII strain specificity through natural
exposure of vivax infection. The target epitopes of anti-DBPII
inhibitory antibody contains variant residues that can alter
antigenic character and antibody recognition [25]. A longitudinal
study to closely observe functional inhibition of anti-DBPII and B-
cell memory response in transmission variation of Thailand will be
required to determine the stability of naturally inhibitory anti-
DBPII response.
The present study confirms the protective potential of
previously identified H1, H2 and H3 epitopes in Thai residents.
Figure 2. Anti-DBPII response and DBPII-Duffy positive erythrocyte inhibitory. Scatter plot showing the correlation between anti-DBPII
levels and inhibition activity among Thai vivax residents (Spearman’s coefficient: 0.042; P=0.764). Fifty-four samples (1:200 diluted plasma) were
tested for their reactivity to DBPII in standard ELISA procedure and for the inhibition function of DBPII binding to Duffy positive erythrocyte measured
by COS7 cell erythrocyte binding assay.
doi:10.1371/journal.pone.0035769.g002
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blocking DBPII-erythrocyte binding of by disruption of DBPII
dimerization necessary for receptor binding [26]. Affinity-purified
antibodies to the Thai DBPII peptides corresponding to the H1
and H3 epitopes showed significant differences in anti-DBPII
inhibition against Sal 1 DBPII compared to the homologous Sal 1
antibodies. However, anti-H3.T2 inhibition still displayed high-
level inhibition activity against DBPII-Sal I binding. The result
suggests that certain mutations at the dimer interface, either
monomorphic (R308S, D384K) or dimorphic mutations (D384K
and K386N), can alter the efficacy of acquired neutralizing
antibody recognition to block DBP function.
Anti-DBPII immunity in Thailand is induced by and targeting
parasitesincirculationintheendemicareas.ThereferencestrainSal
Iisnotcommon,occurring inlowfrequency(10%),and isrestricted
to specific geographic areas [27]. We anticipate that the most
effective strategy of DBPII vaccine will need to effectively target
antigenicallydistinctDBPIIvariants commontotheendemicareas.
In Thailand, phylogenetic analysis showed Thai DBPII variants
form a group with a subset of Papua New Guinea (PNG) and more
related with Korea, India and Colombia isolates [19]. Interestingly,
therearetwo haplotypeunique amongThaiP. vivax.Theprotective
DBPII vaccine candidate in Thai resident will likely require
antibodies directed against all DBPII epitopes of Thai DBPII
variants in circulation among residents. Here, we identify Thai
DBPIIvaccinecandidatesthatareassociatedwithblockingantibody
withThaiDBPIIepitopes.TheprotectiveimmunityofThaivaccine
candidate will require further characterization of Thai anti-DBPII
responsestoevaluatethemosteffectivetargetsofblockingactivityof
antibody against Thai vivax isolates.
Materials and Methods
Ethics
This study was approved by the Committee on Human Rights
Related to Human Experimentation, Mahidol University, and the
Ministry of Health, Thailand (MU-IRB2009/300.012).
The participant information sheet was written and approved by
CommitteeonHumanRightsRelatedtoHumanExperimentation,
Mahidol University, and the Ministry of Health, Thailand. The
informed consent was singed by each individual participant before
the blood sample (20 ml) was collected. The informed consent from
minorityparticipants,pregnantwomanchildren,18 yearwerenot
involvedinthestudy.Bloodsampleswerecollectedfromtheacutely
P. vivax-infected volunteers (n=54), uninfected residents (n=35)
livingatmalariaclinicandfromnonexposedP.vivaxdonors(n=40)
healthy volunteers who live outside the endemic area and without
previous history of malarial infection.
Table 1. Naturally acquired anti-DBPII responses and their







1 19 HR 30.83
2 24 HR 53.41
3 23 HR 52.80
4 23 HR 66.90
5 20 HR 37.63
6 25 HR 65.23
7 48 HR 1.07
8 32 HR 96.42
9 25 HR 58.33
10 21 HR 81.77
11 50 HR 38.54
12 58 HR 98.90
13 38 HR 72.10
14 25 HR 65.60
15 20 HR 61.30
16 36 LR 65.59
17 20 LR 76.61
18 20 LR 78.53
19 30 LR 79.93
20 28 LR 52.30
21 27 LR 39.80
22 23 LR 16.67
23 21 LR 44.44
24 24 LR 88.89
25 39 LR 76.74
26 20 LR 23.50
27 19 LR 57.90
28 23 LR 19.98
29 21 LR 45.70
30 27 LR 32.98
31 30 LR 29.69
32 31 LR 98.20
33 23 LR 77.08
34 21 LR 57.35
35 21 LR 37.50
36 24 LR 37.50
37 27 NR 26.56
38 30 NR 57.90
39 48 NR 50.18
40 50 NR 61.93
41 20 NR 74.56
42 21 NR 73.10
43 24 NR 52.08
44 22 NR 50.18
45 25 NR 73.84
46 38 NR 27.60
47 36 NR 30.47








49 20 NR 56.63
50 20 NR 58.43
51 28 NR 63.09
52 21 NR 64.90
53 27 NR 41.58
54 38 NR 79.50
aHigh responder (HR), Low responder (LR), Non-responder (NR).
doi:10.1371/journal.pone.0035769.t001
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systolic blood pressure was not less than 90 mm, (2) body
temperature was not higher than 40
uC, (3) Hematocrit was not
less than 25% and (4) all patients have to be the age of 18 or above.
Those who were not fitting the criteria were excluded.
Study population
Blood samples were collected from the acutely P. vivax-infected
volunteers (n=54) at Malarial Clinics in Mae-Sod and Mae-Kasa
districts, Tak province. Uninfected residents (n=35) living at both
districts were recruited in the study to compare antibody responses
with vivax patients. In addition, samples from non exposed P. vivax
donors (n=40) healthy volunteers who live outside the endemic
area and without previous history of malarial infection were
included as naı ¨ve controls. The selecting criteria of the patients
were as followings: (1) systolic blood pressure was not less than
90 mm, (2) body temperature was not higher than 40uC, (3)
Hematocrit was not less than 25% and (4) all patients have to be
the age of 18 or above. Those who were not fitting the criteria and
pregnant patients were excluded. After the patients were selected,
20 ml of peripheral venous blood was collected. This study was
approved by the Committee on Human Rights Related to Human
Experimentation, Mahidol University, and the Ministry of Health,
Thailand (MU-IRB2009/300.012). Informed consent was singed
from each individual before the blood sample was collected.
P. vivax cultures and P. vivax crude lysate antigens (PvSE)
preparations
P. vivax-infected blood was used to prepare antigen, P. vivax
schizont extract (PvSE). Briefly, P. vivax infected blood cells was
depleted of white blood cell by filtering through a PlasmodipurH
filter and the red blood cells were washed with RPMI-1640 by
centrifugation at 11906g for 5 min. The parasites were cultured
for 24–30 hrs at 5% haematocrit in McCoy’s medium (GIBCO,
Carlsbad, USA) supplemented with 25% human AB serum at
5%CO2, 5% O2 and 90% N2. After the parasites had matured to
schizont stage, antigens were separated by centrifuged in 60%
Figure 3. The inhibition activity of anti-DBPII epitope-specific antibody to Sal I and Thai strain epitopes. (A) Human antibody specific
to DBPII epitopes strain Sal I; H1, H2, H3 and NI. (B) Antibodies specific to DBPII epitopes Thai strain; H1.T1, H3.T1, H3.T2, H3.T3, M3.T1 and NI. The
purified antibodies were test to determine their inhibitory function against DBPII Sal I binding Duffy positive erythrocyte. The symbol indicates the
mean percentage of inhibition of three experiments compared to the result of control experiment with no antibody. For antibody concentration of 8
ug/mL, the P value was ,0.001 for comparison of H and NI peptides. Significance of inhibition was measured with the 50% inhibition concentration
(1–2 mg/mL) of purified anti- H1, H2, H3 antibodies. (C) Anti-H1 compared with anti-H1.T1; (D) Anti-H3 compared with anti-H3.T3. Antibodies were
tested to determine their inhibitory function against DBPII Sal I binding Duffy positive erythrocyte. The symbol indicates the mean percentage of
inhibition of three experiments compared to the result of control experiment with no antibody. For antibody concentration of 8 ug/mL, the P value
was ,0.001 for comparison of H and NI peptides, and comparison H1.T1, H3.T3 and NI peptides.
doi:10.1371/journal.pone.0035769.g003
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H. The cells in the interface layer between medium and
Percoll
H were collected, washed twice and the pellets were stored
at270
uC to bed used for antibody detection.
Measurement of antibody response to DBPII and PvSE
Anti-PvSE and anti-DBP responses were quantified by ELISA.
The recombinant DBP regions II (rDBPII) was produced as
described previously [14,28]. Briefly, rDBPII was expressed as a
GST fusion protein in E. coli, affinity purified on glutathione and
cleaved from GST with thrombin using standard methods [28,29].
Either 10 mg/mL of PvSE or 2 mg/mL of purified rDBPII-IV was
added to 96-well plates, respectively, incubated for 30 min at room
temperature, and washed three times with wash buffer (0.2%
Tween-20 in PBS). Wells were incubated with 200 mL block buffer
(2% skim milk in PBS) for 30 min, washed three times with wash
buffer, allowed to dry and stored overnight at 4uC. Serum diluted
1:400 in block buffer was added to pre-wetted wells and incubated
for 90 min at 37uC. Plates were rinsed 3x in wash buffer,
incubated with 1:1000 goat anti-human IgG-alkaline phosphatase,
rinsed 3x, and substrate added. Absorbance was recorded at
405 nm at 45 min after addition of developer reagent. A baseline
was established using control sera from non-exposed Thai
residents and this control value was subtracted from the test OD
values. ELISA data was classified into three groups: High
responders (OD=2.24–1.05); Low responders (OD=1.05–0.51);
and Non responders (OD ,0.51). The samples were considered
positive when OD value is $mean +2SD of naı ¨ve controls.
COS7 cell expression of DBP and inhibition assays
COS7 (green monkey kidney epithelial) cells [30] were
transfected with the plasmid (pEGFP-DBPII-Sal 1), which allows
expression of DBPII as a fusion protein to the N-terminus of EGFP
used as a transfection marker as previously described [14]. The
inhibition assay was performed 44 hrs after initial transfection.
Serum at 1:100 dilution or different concentrations of the affinity
purified antibodies were incubated 60 min with transfected COS7
cells followed by incubation with Duffy positive human erythro-
cytes. Unbound erythrocytes were removed by washing three
times with PBS. Binding was quantified by counting rosettes
observed over thirty fields of view at 200x magnification. In this
assay rosettes were defined as COS7 cells covered by bound
erythrocytes at 50% or greater surface area. Percentage inhibition
was calculated for each serum sample relative to binding in
presence of non-exposed Thai residents control serum. Each assay
included a duplicate test of each sample and results were




showed H1: FHRDITFRKLYLKRKL, H2: EGDLLLKLN-
NYRYN and H3: DEKAQQRRKQWWNESK [25]. These
epitopes contain polymorphic residues that may alter the antigenic
recognitionofantibodies.Thereforetodefinewhichpeptidesarethe
strongest DBPII vaccine candidate in Thai residents, the H1, H2
and H3 as well as Thai DBPII peptides which contain the most
common alleles identified in the study Thai population [19] were
synthesized. Therefore, eight DBPII peptides were synthesized
(Table 2). The peptide purity was .90% as determined by high
performance liquid chromatography.
Antibody purification
Antibodies to B-cell epitopes were affinity purified from pooled
human plasma containing high titer DBPII inhibitory antibodies
fromP.vivaxexposedindividualsofThaiorrabbitseraraisedagainst
peptides corresponding to synthesized B-cell epitopes. According to
the manufacturer’s recommended protocol diluted serum was
passed over an affinity column prepared by coupling 3 mg of each
peptidetoaSulfurLinkcouplingresin(Thermoscientific,Rockford,
USA). After washing the column 3x with PBS, pH 7.4, the bound
antibody was eluted with 0.1 M Glycine-HCL pH 3.0 and
immediately neutralized with 1 M Tris-HCL, pH 8.5. Antibodies
were dialyzed against PBS before storage at 220uC until needed.
Data analysis
Classification of high-, low-, and non-responders to DBPII was
based on averaged OD values for three wells per individual; a
baseline was created from naive Thai plasma and subtracted from
test OD values to standardize the ELISA [28]. Cluster analysis was
performed on the ELISA values using SPSS (version 10.0);
individual values clustered in these three distinct groups. High
responders were defined as having OD values .mean +2 STD of
Thai controls and Non-responder sample had OD values ,mean
+1 STD of the control plasma. Non parametric analysis (two
independent samples; Mann-Whitney test) was used for compar-
ison inhibition activity of purified anti-DBPII against H and NI
peptides. The strength of association between percentage inhibi-
tion and anti-DBPII levels was analyzed by the non-parametric
Spearman rank correlation coefficiency (rs).
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H1, H2 and H3 are target epitopes of naturally acquired inhibitory antibodies
[25]. H1.T1, H3.T1, H3.T2, H3.T3 and M3.T1 epitopes are the variant strain
among Thai vivax isolates [19]. NI is the target epitopes of non-inhibitory
antibodies.
doi:10.1371/journal.pone.0035769.t002
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